Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing,…
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company…
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q…
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing…
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in…
MISSISSAUGA, Ontario, Jan. 30, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Diag-Nose.io, a CDL-Seattle graduate, harnesses AI with RhinoMAP™ to redefine respiratory care, securing $2M in oversubscribed fundingSEATTLE, Jan. 30, 2025…